T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease

Abstract Introduction The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress. Methods T2 Protect AD (T2), a phase 2 randomized placebo‐controlled trial of tro...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Aladdin H. Shadyab, Andrea Z. LaCroix, Genevieve Matthews, Daniel Bennett, Alexandre A. Shadyab, Donna Tan, Ronald G. Thomas, Jennifer Mason, Alex Lopez, Brianna Askew, Lia Donahue, Stephen Kaplita, Irfan A. Qureshi, Branko Huisa, Howard H. Feldman, for the Alzheimer's Disease Cooperative Study T2 Protect AD Study Group
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wiley 2022-01-01
סדרה:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
נושאים:	Alzheimer's disease clinical trial drug development pharmacologic recruitment
גישה מקוונת:	https://doi.org/10.1002/trc2.12265
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!